Integrated BioPharma Reports Q3 Loss Amid Revenue Decline

Integrated BioPharma, Inc. reported a notable decline in its financial performance for the quarter ended September 30, 2026. Revenue dropped to $9.9 million, a decrease of $2.8 million or 22% compared to the same period in 2025. This decline impacted the company's bottom line, resulting in an operating loss of $1.0 million, a stark contrast to the operating income of $0.2 million recorded last year.

The net loss for the quarter stood at $0.7 million, contrasting with a net income of $0.1 million a year ago. Earnings per share were affected as well, with a loss of $(0.02) per share compared to break-even results last year. The revenue reduction primarily stemmed from the company's Contract Manufacturing Segment, with the top two customers comprising a significant portion of the total revenue.